These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22580530)

  • 1. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
    Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
    Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
    J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
    Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
    Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
    Ding X; Saxena NK; Lin S; Gupta NA; Anania FA
    Hepatology; 2006 Jan; 43(1):173-81. PubMed ID: 16374859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle.
    Alcántara AI; Morales M; Delgado E; López-Delgado MI; Clemente F; Luque MA; Malaisse WJ; Valverde I; Villanueva-Peñacarrillo ML
    Arch Biochem Biophys; 1997 May; 341(1):1-7. PubMed ID: 9143346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
    Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
    J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes.
    Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML
    J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
    Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
    J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice.
    Lee J; Hong SW; Chae SW; Kim DH; Choi JH; Bae JC; Park SE; Rhee EJ; Park CY; Oh KW; Park SW; Kim SW; Lee WY
    PLoS One; 2012; 7(2):e31394. PubMed ID: 22363635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Storage and Utilization of Glycogen by Mouse Liver during Adaptation to Nutritional Changes Are GLP-1 and PASK Dependent.
    Pérez-García A; Hurtado-Carneiro V; Herrero-De-Dios C; Dongil P; García-Mauriño JE; Sánchez MD; Sanz C; Álvarez E
    Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
    Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
    Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
    Zheng YC
    Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
    Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
    Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes.
    Claus TH; Pan CQ; Buxton JM; Yang L; Reynolds JC; Barucci N; Burns M; Ortiz AA; Roczniak S; Livingston JN; Clairmont KB; Whelan JP
    J Endocrinol; 2007 Feb; 192(2):371-80. PubMed ID: 17283237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
    Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
    Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.